Celavie Biosciences

Celavet Animal Health

Celavie Biosciences Technology

We apply our proprietary technology
across 4 mammalian lines, with all lines expressing similar stem cell markers.

Research in one area feeds the
product pipeline in another area.

Advancing Beyond Mainstream Cell Technology

A key feature of Celavie’s approach, which sets it apart from mainstream stem cell technology, is that the cells are not matured before use, as is the case with embryonic and many adult stem cells. The theoretical premise of this approach is that undifferentiated stem cells are pluripotent and can read cues in the micro environment into which they are injected, becoming any cell type required to repair tissues that have been damaged by chronic disease, use, or trauma.

Celavie uses the latest technological breakthroughs in bioreactors to produce large banks of undifferentiated cells with uniform reproducible and stable qualities. The cells are grown in a specialized patented medium that allows them to maintain their genetic stability over the course of the manufacturing process.


Celavie and Celavet Stem Cells vs. Other Cells

Cell type Potency Healing potential Tumorigenicity Turnaround time Percent stem cells in final formulation
Autologous Adult Stem Cells  
Multipotent
 
Limited
 
No
 
Long
 
Low
Embryonic Stem Calls  
Pluripotent
 
High
 
YES
 
Short
 
High
Induced Pluripotent Cells  
Pluripotent
 
High
 
YES
 
Long
 
Varies
Celavie/Celavet Stem Cells  
Pluripotent
 
High
 
No
 
Short
 
High

Unique Properties of Celavie Stem Cells

Sterility and the integrity of the process are facilitated through the use of the closed-system bioreactor and automated separation and dispensing systems. The manufacturing process utilizes an industry-accepted, multi-tier cell banking system. Every bank of cells is required to meet stringent requirements for viability, genetic stability, and absence of infectious agents prior to being added to a cryobank. When required for treatment, our cells are thawed, reintroduced to the transportation medium, and shipped to the clinical location overnight.

Our technology allows for commercial-scale production and banking of our cells. A single cell line can lead to 13 million therapeutic doses.

Our subsidiary Celavet uses the same standardized and controlled production methods as used in human cell manufacture to establish equine, canine, and feline stem cell lines. Stem cell lines from different species all express standard stem cell characteristics and are available to address pathologies in their respective species.

Clinical Approaches

We believe that Celavie’s stem cells, with their restorative power and their versatility to become multiple tissues, represent humanity’s best hope for a cure for many unaddressed or underserved degenerative diseases and injuries. We have shown in vitro that our stem cells are capable of maturing into a wide range of adult stem cells that can be applied to a number of diseases:

  • Dopamine Producing Neurons for Parkinson’s Disease
  • Calbindin positive Neurons for Cerebellar Ataxia
  • Pancreatic Cells for Diabetes
  • Cardiomyocytes for Myocardial Infarction
  • Tenocytes for Tendon Injuries
  • Fibroblasts for Ligament Injuries
  • Chondrocytes for Joint Injuries
  • Osteoblasts for Bone Injuries

Foundational Theory

Celavie’s undifferentiated cells may:

  • Migrate to the site of the disorder
  • Read the microenvironment into which they are transplanted
  • Multiply and differentiate according to the nature and severity of the disorder
  • Repair structure and restore function

Contact Celavie Biosciences

Changing the Paradigm of Regenerative Medicine and Stem Cell Technology